(Zero Hedge)—Amid the broader debate over artificial intelligence’s economic disruptions, the healthcare sector is quietly demonstrating some of the technology’s most concrete applications. Rather than the job losses feared in other industries, hospitals report AI augmenting physicians, streamlining routine tasks and accelerating innovation in ways that could improve outcomes while controlling costs.
At the Mayo Clinic in Rochester, Minnesota, roughly 150 AI models are now in use. A tool called Record Time helps internists distill hundreds of pages of external medical records into searchable summaries, saving five to 30 minutes per patient, according to CNN.
“AI can step in and do a lot of the tedious work that very specialized doctors or medical professionals do to speed up that process – get to more accurate diagnoses, faster so you can treat more people,” Jason Droege, CEO of Scale AI, said.
Mayo is also testing AI for early pancreatic-cancer detection, potentially years ahead of conventional diagnosis, and for identifying atrial-fibrillation risks that could prevent strokes. The clinic partners with Microsoft and other firms to train models on its vast trove of patient data.
Radiology, once predicted to be AI’s first casualty, tells a similar story of augmentation rather than obsolescence – though the most-cited evidence comes from an interested party. A report from Build American AI – a nonprofit advocacy arm of Leading the Future, the $100 million pro-AI super PAC backed by Andreessen Horowitz and OpenAI executives – finds the U.S. radiologist workforce in Medicare-affiliated practices grew 17.3% between 2014 and 2023. At Mayo itself, the group says, the number of radiologists expanded 55% since 2016. The organization does not disclose its donors and lobbies for federal preemption of state AI rules, so the figures warrant independent checking against Medicare provider data.
Utah recently became the first state to allow an AI system from Doctronic to renew prescriptions for chronic conditions such as diabetes and hypertension. In the pilot’s first five months, the AI recommended approval in 72% of cases, with physicians concurring 91% of the time; it escalated the rest when complications appeared, Forbes reports. The program targets established medications, maintains human oversight and bars controlled substances.
Tampa General Hospital estimates that an AI-enabled sepsis-detection system it built with Palantir has helped save 886 lives since August 2022, cutting early sepsis deaths by 68%. The figure is the hospital’s own assessment of a system developed with a commercial partner.
In drug development, AI’s impact may prove most transformative. A TD Cowen survey of biopharma leaders found executives expect the technology to compress preclinical costs and timelines by as much as 70%, powering in-silico modeling that simulates thousands of experiments rapidly, Axios reports. Respondents expect new drug programs to expand more than 10% in the coming years.
Yet inside the very institutions championing AI, opposition is already brewing.
Mayo Clinic’s former Director of Research Operations Traci Tamiko Eto sued the hospital earlier this month, alleging she was retaliated against for raising privacy and oversight concerns around some Mayo AI systems. Mayo Clinic spokesperson Andrea Kalmanovitz said the hospital doesn’t comment on ongoing litigation but underscored that it is “committed to the responsible development and deployment of AI, with privacy, security, transparency and compliance embedded throughout our processes.”
“Our research and clinical innovation are conducted in accordance with applicable laws and regulations and we remain steadfast in upholding the trust patients place in us and respecting their privacy,” Kalmanovitz said in a statement.
